QB3 Garage@UCSF

Our Facility

The original QB3 Garage, founded in 2006. The QB3 Garage@UCSF features 2,500 square feet of offices, wet laboratory space, and multi-function rooms. Tenants rent at least one office or multi-function room and can then rent a portion of the wet laboratory space. An equipment corridor is also available.

Click here for the Garage@UCSF user’s guide.

Garage tenants can make arrangements to use the following QB3 core facilities:

• UCSF Nikon Imaging Center
• Center for Advanced Technology
• Membrane Protein Expression Center
• Small Molecule Discovery Center
• High Field NMR Biomarker Discovery Facilities
• Cell Culture Facility
• UCSF Mission Bay FAMRI Library
• Micro-Tomography Core Facility
• Micro and Nanofabrication Core
• Resource for Biocomputing, Visualization, and Informatics

Our Location

The QB3 Garage@UCSF is located in 219 Byers Hall on the UCSF Mission Bay campus. Click here for a pdf map of the building. Mission Bay is situated between downtown San Francisco and the Potrero Hill area.

For a map of UCSF Mission Bay, please download this pdf

Tenants

is a company that uses nanoscale particles bound by high density lipoprotein to improve drug delivery.

is a biotechnology company commercializing a revolutionary and proprietary oxygen delivery technology for a broad range of clinical indications in cancer, surgical and cardiovascular markets. Omniox’s biotherapeutic platform was developed at the University of California, Berkeley by a team of outstanding scientists who have engineered a new class of oxygen delivery vehicles with properties that can be exploited for a range of clinical applications. Omniox was founded to translate these vehicles into focused therapeutics.

Oncosynergy

Pivot Bio

SeaChange Pharmaceuticals

uses new computational techniques to identify drugs that may be repurposed, typically for orphan and underserved diseases. SeaChange will run the computational calculations and analysis necessary to expand and test its portfolio of drug ‘off-target’ predictions, which will be validated in vitro by CRO and partnerships.

builds enabling technologies that allow synthetic biologists to accelerate the construction of microbial factories for producing medications, diverse chemicals and novel materials, converting plant material into biofuel, and breaking down toxic waste. Our modular software tools are designed to encompass the entire design/build/test cycle of the forward engineering approach to synthetic biology.

is focused on developing nanoscale therapeutics for oncology.